Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospective Randomized Study

Phiphatpatthamaamphan, Kittichet; Vilaichone, Ratha-Korn; Siramolpiwat, Sith; Tangaroonsanti, Anupong; Chonprasertsuk, Soonthorn; Bhanthumkomol, Patommatat; Pornthisarn, Bubpha; Mahachai, Varocha

doi:10.7314/apjcp.2016.17.4.1903

Cited by 18 publications

(18 citation statements)

References 22 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Curing H. pylori infection still remains a challenge in clinical practice. The 10-day sequential therapy, suggested as first-line therapy in the current Italian guidelines [3], has been proven to be effective in several countries, achieving eradication rates as high as 91.1%-93.7% in Italy [7,11], 92.5-95% in Turkey [12,13], 94.2% in Slovenia [14], 90% in Portugal [15], 90% in Belgium [16], 95.9% in Israel [17], 94% in Thailand [18], 91.9% in Taiwan [19], 90.3% in Singapore [20], and 88.6% in the United Arab Emirates [21]. In detail, the 10-day sequential therapy was found to be equally effective -but cheaper -than J Gastrointestin Liver Dis, March 2019 Vol.…”

Section: Discussionmentioning

confidence: 99%

Sequential Therapy for First-Line Helicobacter pylori Eradication: 10- or 14-Day Regimen?

Zullo

Fiorini

Scaccianoce

et al. 2019

JGLD

View full text Add to dashboard Cite

Background & Aim: Standard 10-day sequential therapy is advised as first-line therapy for Helicobacter pylori (H. pylori) eradication by current Italian guidelines. Some data suggested that a 14-day regimen may achieve higher eradication rates. This study compared the efficacy of sequential therapy administered for either 10- or 14-days.Methods: This prospective, multicenter, open-label study enrolled patients with H. pylori infection without previous treatment. Patients were receiving a sequential therapy for either 10 or 14 days with esomeprazole 40 mg and amoxicillin 1 g (5 or 7 days) followed by esomeprazole 40 mg, clarithromycin 500 mg and tinidazole 500 mg (5 or 7 days), all given twice daily. Bacterial eradication was checked using 13C-urea breath test. Eradication cure rates were calculated at both Intention-to-treat (ITT) and per-protocol (PP) analyses.Results: A total of 291 patients were enrolled, including 146 patients in 10-day and 145 in the 14-day regimen. The eradication rates were 87% (95% CI = 81.5-92.4) and 90.3% (95% CI = 85.5-95.1) at ITT analysis with the 10- and 14-day regimen, respectively, and 92.7% (95% CI = 88.3-97) and 97% (95% CI = 94.2-99.9) at PP analysis (p =0.37). Among patients, who earlier had interrupted therapy, bacterial eradication was achieved in 8 out of 9 who completed the first therapy phase and performed at least ≥3 days of triple therapy in the second phase.Conclusion: This study found that both 10- and 14-day sequential therapies achieved a high eradication rate for first-line H. pylori therapy in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Sequential Therapy for First-Line Helicobacter pylori Eradication: 10- or 14-Day Regimen?

Zullo

Fiorini

Scaccianoce

et al. 2019

JGLD

View full text Add to dashboard Cite

show abstract

“…Patients diagnosed with non-ulcer dyspepsia as established during gastroscopy with normal findings or mild gastritis were included in the study. On the other hand, patients with a history of gastric surgery or those who were taking medications in the preceding four weeks (such as anticoagulants, antibiotics, and proton pump inhibitors) were excluded from the study [22,23]. Participants' demographics such as age, gender, height, and weight were collected using a structured questionnaire, and their clinical history was obtained from their medical files and records.…”

Section: Methodsmentioning

confidence: 99%

The Association between ABCB1 C1236T/C3435T SNPs and H. pylori Infection among Jordanians

Banihani

Khabour

Alzoubi

et al. 2020

Genes

View full text Add to dashboard Cite

Infection with Helicobacter pylori (H. pylori) is very common and affecting about 50% of the worldwide population. Several genetic variations have been implicated in determining the clinical susceptibility to this infection. In the current study, we examined the association between C1236T (rs1045642) and C3435T (rs1045642) single nucleotide polymorphisms (SNPs) in the ABCB1 gene and the prevalence of H. pylori infection among Jordanians. A total of 412 subjects (257 H. pylori-positive cases and 155 H. pylori-negative controls) were recruited and participated in the study, and the genotyping of the ABCB1 gene was performed using RFLP-PCR techniques. A significant association was detected between C1236T and H. pylori infection (p < 0.01). The frequency of CT genotype was significantly higher in the positive cases (40.1%) compared to the controls (21.3%). In addition, the C3435T SNP was weakly associated with H. pylori infection (p = 0.077). Haplotype analysis of C1236T and C3435T SNPs showed that the TT haplotype was present in 22.7% of the positive cases compared to 30.7% of the negative controls (p < 0.05, odds ratio = 0.663, 95% CI: (0.483–0.911)). Consequently, the TT haplotype seems to decrease the risk of H. pylori infection. In conclusion, the current results suggest an association between ABCB1 SNPs and H. pylori infection in the Jordanian population.

show abstract

“…The outcome of CYP2C19 genotype testing were demonstrated as: rapid metabolizer (RM), intermediate metabolizer (IM) or poor metabolizer (PM). CYP2C19 genotypes have effect on pharmacokinetics and pharmacodynamics of PPI which involved in changing gastric pH and effectiveness of H. pylori eradication (Phiphatpatthamaamphan et al, 2016) Currently, H. pylori resistance rates to antibiotics are becoming problem in most parts of the world. H. pylori antibiotic resistance caused eradication rates have been declining while the prevalence of antibiotic resistance rates have been increasing (Malfertheiner et al, 2017) In Thailand, Antibiotic resistance was presented in 50.3% including amoxicillin 5.2%, tetracycline 1.7%, clarithromycin 3.7%, metronidazole 36%, ciprofloxacin 7.7%, Levofloxacin 7.2% and multi-drugs in 4.2% (Vilaichone et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

CYP2C19 Genotype, CagA Genotype and Antibiotic Resistant Strain of Helicobacter pylori Infection

Auttajaroon

Chotivitayatarakorn

Yamaoka

et al. 2019

Asian Pac J Cancer Prev

Self Cite

View full text Add to dashboard Cite

Background: H. pylori is a class I carcinogen and major cause of gastric cancer. Few previous studies reported relationship between H. pylori infection, CYP2C19 genotype and functional dyspepsia (FD) subtype. The aim of this study was to determine relationship between CYP2C19 genotype and FD subtype patients(host factor) with antibiotic resistant strains of H. pylori infection and CagA genotype(bacterial factor). Methods: FD patients who were investigated with gastroscopy at Thammasat University Hospital, Thailand during March 2017-November 2017 were enrolled. Two antral gastric biopsies were obtained for rapid urease test, E-test and cultures. CagA genotypes (CagA1a and CagA2a) were determined by PCR and CYP2C19 genotype was determined by PCR-RFLP. FD patients were categorized as epigastric pain syndrome(EPS) and postprandial distress syndrome (PDS). Results: 93 FD patients with H. pylori infection were enrolled (37 male, 56 female, mean age 54.5 years). There were 33 patients with EPS and 60 patients with PDS. CYP2C19 genotype revealed 55.9% rapid metabolizer (RM), 40.9% intermediate metabolizer (IM) and 3.2% poor metabolizer (PM) genotypes. Antibiotics susceptibility tests demonstrated 62.8% resistant to metronidazole, 12.9% resistant to clarithromycin and 27.1% resistant to fluoroquinolone. CagA 1a and CagA 2a were demonstrated in 6 patients(11.5%) and 46 patients(88.5%). CagA2a genotype was more prevalent in PDS than EPS patients (94.3%vs.76.5%; P =0.08) without significance. In intermediate metabolizer (IM), CagA2a genotype was significant higher in PDS than EPS(100% vs.25%; P=0.004). Conclusions: PDS, CYP2C19 RM genotype and CagA 2a gene of H. pylori infection were the predominant type of FD in Thailand. Metronidazole remain the most common antibiotic resistant strain of H. pylori infection in FD patients. PDS (host factor) was significantly related to CagA2a genotype (bacterial factors) only in patients with intermediate metabolizer. Appropriate dose of proton pump inhibitor (PPI) and correct regimens for H. pylori eradication in FD patients should be consider to improve clinical outcomes.

show abstract

Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospective Randomized Study

Cited by 18 publications

References 22 publications

Sequential Therapy for First-Line Helicobacter pylori Eradication: 10- or 14-Day Regimen?

Sequential Therapy for First-Line Helicobacter pylori Eradication: 10- or 14-Day Regimen?

The Association between ABCB1 C1236T/C3435T SNPs and H. pylori Infection among Jordanians

CYP2C19 Genotype, CagA Genotype and Antibiotic Resistant Strain of Helicobacter pylori Infection

Contact Info

Product

Resources

About